Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET
Company Participants
Richard Lepke – Senior Director, Investor Relations
Marianne De Backer – Chief Executive Officer
Mark Eisner – Executive Vice President & Chief Medical Officer
Jason O’Byrne – Executive Vice President & Chief Financial Officer
Mika Derynck – Executive Vice President of Therapeutic Head Oncology
Conference Call Participants
Gena Wang – Barclays
Paul Choi – Goldman Sachs
Nick Gasic – Leerink Partners
Phil Nadeau – TD Cowen
Patrick Trucchio – H.C. Wainwright & Co.
Joseph Stringer – Needham & Company
Operator
Hello. Welcome to Vir Biotechnology’s First Quarter 2025 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time, all participants are in a listen-only mode. After the speakers presentation, there will be a question-and-answer session.
I will now turn the call over to Rich Lepke, Senior Director, Investor Relations. You may begin, Mr. Lepke.
Richard Lepke
Thank you and good afternoon. With me today are Dr. Marianne De Backer, our Chief Executive Officer; Dr. Mark Eisner, our Chief Medical Officer; Jason O’Byrne, our Chief Financial Officer; and Dr. Mika Derynck, our Executive Vice President of Oncology, who will be available during the Q&A session.
Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the company’s reports filed with the Securities and Exchange Commission, including Forms 10-K, 10-Q and 8-K.
I will now turn the